The Integrated Forecasting and Analysis Tool   Login Now

AVANT Immunotherapeutics

EvaluatePharma® delivers unique insight into the past and future performance of companies in the pharmaceutical and biotechnology sector, in a user-friendly, online subscription service. A small selected sample of reports and related news headlines for AVANT Immunotherapeutics are available below. Free sample reports are also available for other Companies. To find out how you can access more detailed information on AVANT Immunotherapeutics, or on any other Company covered by EvaluatePharma® Contact Us today.

PIPELINE ANALYSIS - Sales Forecasts available to EvaluatePharma Subscribers

Rank Product Therapeutic Category Therapeutic Subcategory Pharmacological Class Phase (Current) AVANT Immunotherapeutics - TP10 Oncology & Immunomodulators Immunosuppressants Complement inhibitor Phase II   - TP20 Oncology & Immunomodulators Immunosuppressants Complement & selectin inhibitor Pre-clinical   - CholeraGarde Systemic Anti-infectives Vaccines Cholera vaccine Phase II

FINANCIAL DATA ($US mln) - Forecasts available to EvaluatePharma Subscribers

AVANT Immunotherapeutics   2005 2006  Valuation Measures   Based on Latest Share Prices      Valuing the Equity        Market Capitalisation 257 257        PE Ratio (diluted) - Normalised (x) (5.9) (5.2)        Valuing the Enterprise        Enterprise Value 236 236        Free Cash Flow (Pre-Dividends) (8) 18        FCF Yield (%) (3.5%) 7.6%    Forecast Financials   Income Statement      Total Revenues 3 5      S,G & A (7) (8)      R&D (14) (18)      Other Income/ Expense - Net (1) (1)      EBIT - Normalised (19) (22)      Net Interest & Financial Items 1 2      Pre-tax Profits - Normalised (18) (20)      Income Before Taxes (18) (20)      Tax 0 0      Tax Rate (%) 0.0% 0.6%      Net Income - Reported (18) (20)      Net Income - Normalised (18) (20)     Per Share Data      EPS - Diluted (2.93) (3.29)      EPS - Basic (2.93) (3.29)      EPS - Normalised (diluted) (2.93) (3.29)      EPS - Normalised (basic) (2.93) (3.29)      Avg. Shares Outstanding - Diluted 6.2 6.2      Avg. Shares Outstanding - Basic 6.2 6.2      DPS 0.00 0.00

NEWS - Selected Product News Headlines (as of 11 June 2008)

NIH Initiates Phase 1 Safety Study of AVANT's Oral Combined Enterotoxigenic E. coli-Cholera Vaccine   (AVANT Immunotherapeutics)   04-Jun-2008 Updated CDX-110 Data in Glioblastoma Multiforme Presented at 44th Annual ASCO Annual Meeting   (Pfizer)   02-Jun-2008 Significant Tumor-Specific Immune Response Observed in AVANT's Phase 2 Trial Evaluating CDX-110 with Temozolomide for Treatment of Glioblastoma Multiforme   (AVANT Immunotherapeutics)   15-Apr-2008 FDA Approves ROTARIX(R) Rotavirus Vaccine   (AVANT Immunotherapeutics)   04-Apr-2008 FDA Approves ROTARIX(R) [Rotavirus Vaccine, live, oral], the First Vaccine Licensed to Complete the Rotavirus Immunization Series by Four Months of Age   (GlaxoSmithKline)   03-Apr-2008 AVANT's Single-Dose Oral Ty800 Vaccine Meets Primary Endpoints in Phase 2 Study   (AVANT Immunotherapeutics)   01-Apr-2008 Rotarix(R) Receives Favorable Recommendation from FDA Advisory Committee   (AVANT Immunotherapeutics)   21-Feb-2008 GSK Receives Favorable Recommendation by FDA Advisory Committee for Rotarix(R) (Rotavirus Vaccine, Live, Oral)   (GlaxoSmithKline)   20-Feb-2008 Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma   (Celldex Therapeutics)   07-Jan-2008 Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme   (Celldex Therapeutics)   07-Dec-2007 AVANT Immunotherapeutics Achieves Immune Responses Against Cholera, Typhoid and Enterotoxigenic E. coli with a Single-Dose, Oral Combination Vaccine   (AVANT Immunotherapeutics)   05-Dec-2007 AVANT's Partner, GlaxoSmithKline, Announces New Data Published in The Lancet Show That Rotarix(R) Provides Sustained and Broad Protection During the First Two Years of Life(1)   (AVANT Immunotherapeutics)   26-Nov-2007 New Data Published in the Lancet Show Gsk’s Rotavirus Vaccine Rotarix® Offers Sustained and Broad Protection Against All Common Circulating Rotavirus Types   (GlaxoSmithKline)   23-Nov-2007 AVANT's Oral Combined Enterotoxigenic E. coli-Cholera Vaccine to Enter Phase 1 Safety Study Funded by the NIH   (AVANT Immunotherapeutics)   19-Nov-2007 GlaxoSmithKline’s Application for Rotarix® is Accepted for Review by the FDA   (GlaxoSmithKline)   16-Aug-2007 Application for Rotarix(R) by AVANT's Partner, GlaxoSmithKline, is Accepted for Review by the FDA   (AVANT Immunotherapeutics)   14-Aug-2007 AVANT Commences Phase 2 Clinical Trial of Its Single Dose, Oral Typhoid Fever Vaccine   (AVANT Immunotherapeutics)   30-Jul-2007 AVANT's Partner, GlaxoSmithKline, Files Rotarix(R) Application for U.S. Marketing Approval with the FDA   (AVANT Immunotherapeutics)   27-Jun-2007

IN-DEPTH COMPETITIVE INTELLIGENCE AVAILABLE ON

Product Generic Name AVANT Immunotherapeutics Anthrax & Plague Vaccine anthrax & plague vaccine   Anthrax Vaccine (2nd generation) anthrax vaccine   Anthrax Vaccine (3rd generation) anthrax vaccine   ATM 027 -   ATP 012 -   Avian Flu Vaccine avian influenza vaccine   Campylobacter vaccine campylobacter vaccine   CDX-110 -   CDX-1307 -   CDX-1401 -   CDX-2101 (inc. Ribi-529 adjuvant) -   CDX-2301 -   CDX-2401 -   CDX-2410 -   CDX-S03 -   CETi-1 Vaccine -   Cholera/Typhoid/ETEC E. coli cholera, typhoid & ETEC vaccine   CholeraGarde cholera vaccine   dl5-29 HSV-2 vaccine herpes simplex virus vaccine   ETEC E. coli Vaccine ETEC vaccine   ETEC E. coli/Cholera Vaccine ETEC & cholera vaccine   Influenza Vaccine influenza vaccine   Influenza Vaccine Project (Select Vaccines) influenza vaccine   Lyme Disease Vaccine lyme disease vaccine   MAGE3 -   MelanA -   Mirococept (APT070) -   NY-ESO-1 -   Rotarix rotavirus vaccine   RSV Vaccine RSV vaccine   Shigella sonnei Vaccine shigella sonnei vaccine   Therapore Cancer Vaccine -   Therapore Hepatitis Vaccine hepatitis B & C vaccine   Therapore HIV Vaccine HIV vaccine   TP10 -   TP20 -   Ty800 Typhoid Fever typhoid vaccine   VaxImmune.Cholesterol (AVANT CETP Vaccine) -

EvaluatePharma® provides historic and forecast sales from 1986 to 2012 for worldwide and US Rx (prescription drugs) and OTC drugs. EvaluatePharma® analysts continuously update company models from SEC filings, annual reports, investor/analyst presentations, company press releases, FDA and USPTO. Consensus forecasts for marketed and emerging products are built-up using recent research reports from top equity analysts. Analyse pharma and biotech products by market status or development phase (e.g., preclinical, phase I, phase II, phase III, filed, approved, withdrawn, disposed etc), therapeutic category, product sourcing strategy, patent expiry and patent life remaining, originator, technology, indication, pharmacological class, deal dates, deal types and partners, launch dates, FDA approval data and new molecular entity (NME) age - plus many more data items and analytics unique to EvaluatePharma®. Aggregations of these measures at a high-level means that companies may be ranked against each other on items such as: market capitalization, patent risk, R&D spend, freshness index, sales strategy (inlicensed vs organic sales), sales by therapy area or technology and various other concentration measures. These aggregations make EvaluatePharma® ideal for competitive benchmarking, ranking and Peer Group analysis. Note: When a merger or acquisition is agreed, a virtual merged Company will be added to the list of available Company reports. Any information presented for a virtual merged company is for illustrative purposes, only.

Source: EvaluatePharma ®

Generated at 13:56:30 (GMT) on 11-Jun-2008

© 2008 EvaluatePharma Ltd